KROS vs REGN
KROS: Clinical-stage biotech developing TGF-beta-targeting protein therapeutics for rare neuromuscular and hematologic diseases with one Phase 3 program licensed to Takeda. REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas.
Side-by-side fundamentals
| Metric | KROS | REGN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.21 | $651.18 | |
| Market cap as of 2026-07-23 | $202M | $70.6B | |
| P/E as of 2026-07-23 | 2.32 | 15.95 | KROS lower |
| PEG as of 2026-07-23 | -0.00 | 1.01 | KROS lower |
| Net margin as of 2026-07-23 | -256.6% | +29.6% | REGN higher |
| Gross margin as of 2026-07-23 | n/a | +85.7% | |
| Operating margin as of 2026-07-23 | -332.6% | +24.3% | REGN higher |
| ROE as of 2026-07-23 | -17.0% | +14.3% | REGN higher |
| ROA as of 2026-07-23 | -15.8% | +11.1% | REGN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.09 | KROS lower |
| Revenue growth (YoY) as of 2026-07-23 | -84.5% | +5.9% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.6% | |
| Dividend yield as of 2026-07-23 | n/a | +0.6% | |
| Beta as of 2026-07-23 | 1.01 | 0.21 | |
| 1-year return as of 2026-07-22 close | -23.4% | +16.1% | REGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.